Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer.

Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H.

FASEB J. 2011 Apr;25(4):1198-207. doi: 10.1096/fj.10-167924. Epub 2010 Dec 21.

PMID:
21177307
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity.

Lee YH, Kwak J, Choi HK, Choi KC, Kim S, Lee J, Jun W, Park HJ, Yoon HG.

Int J Mol Med. 2012 Jul;30(1):69-74. doi: 10.3892/ijmm.2012.966. Epub 2012 Apr 10.

PMID:
22505206
[PubMed - indexed for MEDLINE]
3.

Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo.

Lee SC, Chan WK, Lee TW, Lam WH, Wang X, Chan TH, Wong YC.

Nutr Cancer. 2008;60(4):483-91. doi: 10.1080/01635580801947674.

PMID:
18584482
[PubMed - indexed for MEDLINE]
4.

Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.

Harper CE, Patel BB, Wang J, Eltoum IA, Lamartiniere CA.

Prostate. 2007 Oct 1;67(14):1576-89.

PMID:
17705241
[PubMed - indexed for MEDLINE]
5.

Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells.

Ren F, Zhang S, Mitchell SH, Butler R, Young CY.

Oncogene. 2000 Apr 6;19(15):1924-32.

PMID:
10773882
[PubMed - indexed for MEDLINE]
Free Article
6.

Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells.

Ahmad N, Gupta S, Mukhtar H.

Arch Biochem Biophys. 2000 Apr 15;376(2):338-46.

PMID:
10775421
[PubMed - indexed for MEDLINE]
7.

Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents.

Agarwal R.

Biochem Pharmacol. 2000 Oct 15;60(8):1051-9. Review.

PMID:
11007941
[PubMed - indexed for MEDLINE]
8.
9.

Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.

Mashima T, Okabe S, Seimiya H.

Mol Pharmacol. 2010 Nov;78(5):846-54. doi: 10.1124/mol.110.064790. Epub 2010 Aug 13.

PMID:
20709811
[PubMed - indexed for MEDLINE]
Free Article
10.

Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.

Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM, Jenster G.

PLoS One. 2011;6(8):e23144. doi: 10.1371/journal.pone.0023144. Epub 2011 Aug 4.

PMID:
21829708
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells.

Siddiqui IA, Adhami VM, Afaq F, Ahmad N, Mukhtar H.

J Cell Biochem. 2004 Feb 1;91(2):232-42.

PMID:
14743383
[PubMed - indexed for MEDLINE]
12.

Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.

Dehm SM, Tindall DJ.

J Biol Chem. 2006 Sep 22;281(38):27882-93. Epub 2006 Jul 25.

PMID:
16870607
[PubMed - indexed for MEDLINE]
Free Article
13.

Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.

Dai Y, Ngo D, Jacob J, Forman LW, Faller DV.

Carcinogenesis. 2008 Sep;29(9):1725-33. doi: 10.1093/carcin/bgn117. Epub 2008 May 16.

PMID:
18487222
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.

Ozers MS, Marks BD, Gowda K, Kupcho KR, Ervin KM, De Rosier T, Qadir N, Eliason HC, Riddle SM, Shekhani MS.

Biochemistry. 2007 Jan 23;46(3):683-95.

PMID:
17223690
[PubMed - indexed for MEDLINE]
15.

Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.

Minamiguchi K, Kawada M, Ohba S, Takamoto K, Ishizuka M.

Mol Cell Endocrinol. 2004 Feb 12;214(1-2):175-87.

PMID:
15062556
[PubMed - indexed for MEDLINE]
16.

Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer.

Narizhneva NV, Tararova ND, Ryabokon P, Shyshynova I, Prokvolit A, Komarov PG, Purmal AA, Gudkov AV, Gurova KV.

Cell Cycle. 2009 Dec 15;8(24):4155-67. Epub 2009 Dec 13.

PMID:
19946220
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.

Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D.

J Urol. 1999 Dec;162(6):2192-9.

PMID:
10569618
[PubMed - indexed for MEDLINE]
18.

Molecular targets for green tea in prostate cancer prevention.

Adhami VM, Ahmad N, Mukhtar H.

J Nutr. 2003 Jul;133(7 Suppl):2417S-2424S. Review.

PMID:
12840218
[PubMed - indexed for MEDLINE]
Free Article
19.

SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer.

Thomas R, Sharifi N.

Mol Cancer Ther. 2012 Jan;11(1):87-97. doi: 10.1158/1535-7163.MCT-11-0540. Epub 2011 Dec 15.

PMID:
22172488
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.

Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, Liao S.

Cancer Lett. 2009 Mar 8;275(1):86-92. doi: 10.1016/j.canlet.2008.10.001. Epub 2008 Nov 1.

PMID:
18977589
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk